Key Considerations for Roivant Sciences Investors

By Susan Ramirez • Friday, January 19 13:13 • Permanent Link

More and more people are talking about Roivant Sciences over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $10.32? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Roivant Sciences has moved 19.7% over the last year, and the S&P 500 logged a change of 20.3%
ROIV has an average analyst rating of buy and is -35.5% away from its mean target price of $16.0 per share
Its trailing earnings per share (EPS) is $-1.47
Roivant Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -7.0 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.16 and its forward P/E ratio is -8.9
The company has a Price to Book (P/B) ratio of 8.72 in contrast to the S&P 500's average ratio of 2.95
Roivant Sciences is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-476754880, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.